similarly , although favourable clinical results have been obtained in patients treated with ceftizoxime for infections caused by mixed aerobic/anaerobic organisms ( such as intra-abdominal , and obstetric and gynaecological infections ) , the relatively low in vitro activity of ceftizoxime ( in common with most other third generation cephalosporins ) against bacteroides fragilis and enterococci may restrict its usage in situations where these organisms are the suspected or proven pathogens .
C0029235
organisms
C0450254
pathogens